iiinova — where your digital self keeps evolving

The Lancet Oncology @thelancetoncol.bsky.social · 29/09/2026

🆕Our October issue is live! 📊Articles: #ovariancancer, #breastcancer, #multiplemyeloma, #prostatecancer, #lungcancer 📉Trials: KEYLYNK-001, CHN HYPOPMRT, SYMPRO-Lung trial, OPTIMUM/MUKnine, STAMINA 🎨Cover: Cancer & the microbiome Read here: thelancet.com/issue/S1470-...

110

The Lancet Oncology @thelancetoncol.bsky.social · 25/09/2026

Just launched: Accelerating equitable cancer genomics and precision oncology in health care and research: a @thelancetoncol.bsky.social Commission With a new framework, implementation could be more equitable, effective, and sustainable Read more: thelancet.com/commissions-...

001

Reposted by The Lancet Oncology

The Lancet @thelancet.com · 25/09/2026

Cancer genetic testing and precision oncology are advancing rapidly—but access is not. A new @thelancetoncol.bsky.social Commission sets out how health systems can scale these innovations equitably and sustainably: spkl.io/633287TYKi #WCC2026

Lancet infographic containing four scatter graphs showing precision oncology research is predominantly in countries with higher income, not higher cancer deaths. Under the graphs are a microscope, money bag, and graduation cap with arrows pointing up next to them. The three images represent 'more research infrastructure', 'more industry investment', and 'more academic capcity', respectively, as the reasons for the imbalance.

Lancet infographic containing an upside-down triangle graphic with four numbered sections. Next to the triangle is a table detailing a four-tier UHC framework for prioritising precision oncology interventions. The four tiers are Essential, Core expansion, Conditional, Evidence generation.

Lancet infographic representing the practical context-sensitive instrument for health systems planners and policy makers accompanying a four-tier UHC framework for prioritising precision oncology interventions. In one circle, there is a traffic light on green representing 'A system-readiness tool'. In a second circle is a person, light bulb, and cog system representing 'A workforce competency framework. In a third circle, there is a bar graph with an eye in a magnifying glass in front of it representing 'A monitoring and evaluation framework'.

0116

The Lancet Oncology @thelancetoncol.bsky.social · 23/09/2026

🚨Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial 📑Read here: thelancet.com/journals/lan... 📺Watch here: youtu.be/3OH_3uAj-xE?...

youtu.be

Radiotherapy after Mastectomy: 5-Year Results

YouTube video by The Lancet

012

The Lancet Oncology @thelancetoncol.bsky.social · 23/09/2026

🔴Online now: Global health expenditures on cancer control: a cross-sectional analysis "By making cancer expenditures visible and comparable, this work helps create an evidence base to inform priority setting and allocation decisions for cancer control." thelancet.com/journals/lan...

022

The Lancet Oncology @thelancetoncol.bsky.social · 18/09/2026

Attending #WorldCancerCongress #WCC2026 in Hong Kong? Join us for the launch of the new @thelancetoncol.bsky.social Commission on Accelerating equitable cancer genomics and precision oncology Friday Sept 25, 2026 at 11:10 AM (Asia/Hong Kong)

010

The Lancet Oncology @thelancetoncol.bsky.social · 15/09/2026

🔴Online now: Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial thelancet.com/journals/lan...

000

The Lancet Oncology @thelancetoncol.bsky.social · 10/09/2026

📽️Watch now: Unpicking the UK's cancer response after Brexit: what broke, what was patched up, and what still matters Read the full Essay in @thelancetoncol.bsky.social youtu.be/HIYHaqbK9UY?...

youtu.be

The UK's Cancer Care after Brexit

YouTube video by The Lancet

010

The Lancet Oncology @thelancetoncol.bsky.social · 04/09/2026

🎧Listen & subscribe to our Sept podcast: Prof Sherene Loi and the International Immuno-Oncology Biomarker Working Group on TILs in breast cancer Spotify: open.spotify.com/show/3JOj0Cl... Apple: podcasts.apple.com/us/podcast/t... Sept issue: www.thelancet.com/issue/S1470-...

000

The Lancet Oncology @thelancetoncol.bsky.social · 28/08/2026

Looking forward to this year's #WorldCancerCongress #WCC2026 where our Editor-in-Chief will be chairing three sessions including two on Commissions from @thelancetoncol.bsky.social and a Rapid Fire session on some of the latest research. See you in Hong Kong!

000

The Lancet Oncology @thelancetoncol.bsky.social · 25/08/2026

🆕Our Sept issue is now live! 📊Articles: #hepatocellularcarcinoma #NSCLC #rectalcancer #breastcancer #prostatecancer 📉Featuring trials: EMERALD-3, HARMONi, ALINA, STAR-TREC, & GETUG AFU 18 🎨Cover: breast cancer, TILs, and AI 🖱️Read here: www.thelancet.com/issue/S1470-...

003

The Lancet Oncology @thelancetoncol.bsky.social · 24/08/2026

🔴Online now: ChemoRT vs short-course RT for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of a randomised, phase 2/3 trial 📉Article: thelancet.com/journals/lan... & ✏️ Comment: thelancet.com/journals/lan...

013

Reposted by The Lancet Oncology

The Lancet @thelancet.com · 04/08/2026

Triple-negative breast cancer is the most aggressive form of the disease, & it often spreads to the brain. Treatment options remain limited. A Review in @thelancetoncol.bsky.social draws together the latest evidence to provide a roadmap for unmet clinical needs. Find out more: tinyurl.com/3s3nez22

tinyurl.com

Novel strategies to overcome the blood–brain barrier in triple-negative breast cancer brain metastases

Triple-negative breast cancer—the most aggressive breast cancer subtype—has a high propensity for brain metastases, with limited treatments and poor prognosis. The blood–brain barrier, long viewed as ...

063

Reposted by The Lancet Oncology

eClinicalMedicine – The Lancet Discovery Science @eclinicalmed.bsky.social · 04/08/2026

📢Register now for our free #Webinar "Transforming the Landscape of #GynaecologicalCancer: Advances in Prevention, Precision Surgery, and Innovative Systemic Therapies" on Sept 3: irc.ad/the-lancet-g... Read the linked Series here: thelancet.com/series-do/gy... @chrustrasbourg.bsky.social

087

The Lancet Oncology @thelancetoncol.bsky.social · 28/07/2026

🆕Our Aug issue is live! 📊Articles: #bladdercancer #Breastcancer #urothelialcarcinoma #NSCLC 📉Trials: HORIZON-Breast01, SERENA-6, SUPREMO, JCOG1403, BOND-003, PICC-2, PERISCOPE II 🎨Cover: Advancing oncology education in LMIC African settings 🖱️https://www.thelancet.com/issue/S1470-2045(26)X2007-1

011

The Lancet Oncology @thelancetoncol.bsky.social · 15/07/2026

🚨Online now: Efficacy and safety of dabrafenib plus trametinib in adults with differentiated #thyroidcancer: a randomised, double-blind, placebo-controlled, phase 3 trial 📊Read here: thelancet.com/journals/lan... 📝Linked comment: thelancet.com/journals/lan...

001

The Lancet Oncology @thelancetoncol.bsky.social · 02/07/2026

🚨Our July podcast! Hans Merks on European guidelines for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma 🎧Listen & subscribe: Spotify open.spotify.com/show/3JOj0Cl... Apple podcasts.apple.com/us/podcast/t... 📕Read here: www.thelancet.com/pdfs/journal...

010

The Lancet Oncology @thelancetoncol.bsky.social · 01/07/2026

Ready to share your #ClinicalOncology research with millions globally? Explore our author resources for a seamless submission process, and start your publication journey with us today: hubs.li/Q04mkDC40

000

The Lancet Oncology @thelancetoncol.bsky.social · 01/07/2026

Behind every paper is a community. To every author who trusted us with their research and every peer reviewer who gave their time and expertise—thank you! Together, we are advancing the best science for better lives. Learn about our peer review process: hubs.li/Q04mCzF70

010

The Lancet Oncology @thelancetoncol.bsky.social · 01/07/2026

We are an internationally trusted journal for clinical and global #oncology, with a:   Journal Impact Factor of 33·7  Scopus CiteScore of 42·0  Explore our high impact and global reach: hubs.li/Q04k_cRQ0 #ClinicalOncology #MedicalResearch #ClinicalTrials

hubs.li

About The Lancet Oncology

000

The Lancet Oncology @thelancetoncol.bsky.social · 30/06/2026

✏️Our July Editorial: Historic moments "Attending large scientific conferences can be an endurance test....but occasionally, it becomes apparent that the conference in question is different, that something historic has happened." Read here: thelancet.com/journals/lan...

000

Reposted by The Lancet Oncology

European Organisation for Research and Treatment of Cancer @eortc.org · 30/06/2026

📢 New @thelancetoncol.bsky.social publication insights from EORTC trial 22922/10925 focusing on an unplanned subset analysis of patients with node-negative (pN0) breast cancer with centrally or medially located tumours. 🎥 Watch video & learn more: www.eortc.org/blog/2026/05... #EORTCbreast

001

The Lancet Oncology @thelancetoncol.bsky.social · 30/06/2026

🆕Our July issue is live! 📊Articles: #NSCLC #Breastcancer #prostatecancer #glioblastoma 📉Trials: AENEAS2, SUBITO, EORTC 22922/10925, ARTO, PRIMARY2, CAIRO6, & INTRAGO-II 🎨Cover: Meta-analysis on AEs of CD3 T cell-engaging bispecific abs Read here: thelancet.com/issue/S1470-...

022

The Lancet Oncology @thelancetoncol.bsky.social · 02/06/2026

🆕Our June issue is live! 📊Articles: #prostatecancer, #breastcancer, #kidneycancer, #RCC, #glioma 📉Including trials: CAN-2409, FAST-Forward, OCLURANDOM, FASTRACK, & UNITED ✏️Perspective: Equity in Germany's National Lung Cancer Screening Read here: thelancet.com/issue/S1470-...

010

The Lancet Oncology @thelancetoncol.bsky.social · 31/05/2026

🚨 Attend the #ASCO26 session today: A Workforce Crisis—A Lancet Oncology Commission May 31, 2026, 4:30 PM-5:45 PM CDT at #ASCO 📕Booklet available at outside session and online 🖱️http://thelancet.com/commissions-do/cancer-workforce 📽️ youtu.be/VYr2Bjmxyhg

youtu.be

Cancer workforce—a global crisis

YouTube video by The Lancet

020

The Lancet Oncology @thelancetoncol.bsky.social · 28/05/2026

Heading to #ASCO26? Reach out to Dr David Collingridge, Editor-in-Chief at @thelancetoncol.bsky.social, attending #ASCO26 🗓️ Attend the Global Oncology: A Workforce Crisis—A Lancet Oncology Commission session May 31, 2026, 4:30 PM-5:45 PM CDT #cancerworkforce meetings.asco.org/meetings/202...

012

The Lancet Oncology @thelancetoncol.bsky.social · 14/05/2026

Heading to #ESTRO26? Attend our Top Clinical Trials session, May 17 Reach out to Cheryl Lai, Deputy Editor at @thelancetoncol.bsky.social, attending #ESTRO and say hello!

010

The Lancet Oncology @thelancetoncol.bsky.social · 30/04/2026

🎧Our May podcast: Cheryl Lai is joined by Fred Saad (Montreal) to discuss pain and HRQOL outcomes from the ARANOTE trial in metastatic hormone-sensitive prostate cancer 📊Article: www.thelancet.com/journals/lan... Spotify: open.spotify.com/episode/1EGt... Apple: podcasts.apple.com/us/podcast/t...

001

The Lancet Oncology @thelancetoncol.bsky.social · 29/04/2026

Join IARCWHO for the #IARC60 conference in Lyon, France, May 19-21. Learn from your peers from around the world how you can improve cancer prevention in your setting. Register: iarc2026conf.iarc.who.int/en/registrat...

000

The Lancet Oncology @thelancetoncol.bsky.social · 29/04/2026

🆕Our May issue is live! 📊Articles: #breastcancer, #prostatecancer, and #softtissuesarcoma 📑Reviews: Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer from the EORTC–ESTRO OligoCare consortium Read here: thelancet.com/issue/S1470-...

010

The Lancet Oncology @thelancetoncol.bsky.social · 13/04/2026

Cancer prevention isn’t the same in every country, but every local breakthrough advances global progress. Join IARCWHO for the #IARC60 conference. Learn from your peers from around the world how you can improve cancer prevention in your setting. Register: iarc2026conf.iarc.who.int/en/registrat...

020

Reposted by The Lancet Oncology

The Lancet @thelancet.com · 02/04/2026

🆕 Introducing The Lancet Regional Health – Eastern Mediterranean, a new #goldopenaccess journal promoting the advancement of clinical practice and health policy in the Eastern Mediterranean. Discover the new addition to The Lancet Group at: spkl.io/63328AFIyw #medsky

Promotional card announcing the launch of The Lancet Regional Health - Eastern Mediterranean. Text on card reads: Discover a new open access journal advancing clinical practice and health policy in the Eastern Mediterranean. Image depicts a woman sitting in a chair while speaking to a doctor holding an electronic tablet.

037

The Lancet Oncology @thelancetoncol.bsky.social · 02/04/2026

This month's podcast: James Nagarajah on [177Lu]-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study 🎧 Listen & subscribe! Spotify: open.spotify.com/show/3JOj0Cl... Apple: podcasts.apple.com/us/podcast/t...

032

The Lancet Oncology @thelancetoncol.bsky.social · 31/03/2026

✏️Our Editorial: The promise of telesurgery in oncology thelancet.com/journals/lan...

000

The Lancet Oncology @thelancetoncol.bsky.social · 31/03/2026

🆕Our April issue is live! 📊Articles: #NSCLC, #bladdercancer, #melanoma, #prostatecancer, #breastcancer 📰Reviews: A PSOGI–ESGO–ISSPP Lyon consensus & OPTIMISE-AR recommendations for visualising PROs Cover: Spaceflight as a cancer research catalyst www.thelancet.com/issue/S1470-...

032

The Lancet Oncology @thelancetoncol.bsky.social · 12/03/2026

@thelancetoncol.bsky.social are proud to be media partners of #IARC@60 Conference #IARCWHO has selected the successful authors from the ~1300 abstracts submitted from all over the world. Register here: iarc2026conf.iarc.who.int/en/registrat...

iarc2026conf.iarc.who.int

Registration | IARC @60 conference - 19-21 May 2026 - Lyon, France

000

The Lancet Oncology @thelancetoncol.bsky.social · 05/03/2026

In our March Editorial, we discuss England's National Cancer Plan, launched on Feb 4. The plan sets out ambitious targets, but will these be met? Read England's National Cancer Plan: hollow promises? here:🖱️https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00077-X/fulltext#f10

000

The Lancet Oncology @thelancetoncol.bsky.social · 03/03/2026

🎧 Our March podcast: We talk to Dylan Graetz and Erica Kaye @stjuderesearch.bsky.social about qualitative research in oncology thelancet.com/multimedia/p... Follow In Conversation With Spotify: open.spotify.com/show/3JOj0Cl... Apple: podcasts.apple.com/us/podcast/t...

042

The Lancet Oncology @thelancetoncol.bsky.social · 03/03/2026

🆕Our March issue is live! 📊Articles: #prostatecancer, #breastcancer, #melanoma, and #brachytherapy 📰Reviews: #ESTRO concensus on RT for more efficacious novel anticancer drugs + a expert consensus on oligometastatic pancreatic cancer www.thelancet.com/issue/S1470-...

002

Reposted by The Lancet Oncology

The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 17/02/2026

A clinical trial from @thelancetoncol.bsky.social explores whether advanced PET imaging improves outcomes over standard MRI for guiding re-irradiation in recurrent glioblastoma. It aligns with our journal's focus on how imaging influence treatment & patient lives 🔓https://bit.ly/thelancet-lanonc-642

012

The Lancet Oncology @thelancetoncol.bsky.social · 18/02/2026

We are happy to be media partners with the European Association for Cancer Research (EACR) for the #EACR2026 Congress: Innovative Cancer Science in Budapest, Hungary; June 8–11, 2026 Submit your abstract by March 4, 2026: 2026.eacr.org

000

The Lancet Oncology @thelancetoncol.bsky.social · 06/02/2026

🔴Online now: Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised #prostatecancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial thelancet.com/journals/lan...

002

Reposted by The Lancet Oncology

The Lancet @thelancet.com · 04/02/2026

On #WorldCancerDay, stay up to date with the latest oncology content published across The Lancet Group. Explore our Specialty Collection: spkl.io/63327AsDNU

(CAR) T-cell therapy. Composite coloured scanning electron micrograph (SEM) of T-cells (small round) and an apoptotic cervical cancer cell (Hela). Copyright: STEVE GSCHMEISSNER / SCIENCE PHOTO LIBRARY

085

The Lancet Oncology @thelancetoncol.bsky.social · 04/02/2026

🆕 Greater transparency for oncology clinical trials reporting Chief Editors of The Lancet’s specialty journals discuss enhanced scrutiny in the reporting of oncology clinical trials Read here: thelancet.com/journals/lan...

012

The Lancet Oncology @thelancetoncol.bsky.social · 03/02/2026

✏️February's Editorial - Cancer: another casualty of geopolitical unrest? We discuss the deprioritisation of health care during geopolitical instability www.thelancet.com/journals/lan...

021

The Lancet Oncology @thelancetoncol.bsky.social · 03/02/2026

🆕Our Feb issue is live! 📉Articles: #NSCLC, #glioblastoma, #prostatecancer, #oesophagealcancer, and #coloncancer 📰Reviews: International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression AND ReCOG consensus on multiple courses of RT thelancet.com/issue/S1470-...

032